@article{ref1,
title="Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up study",
journal="Journal of child and adolescent psychopharmacology",
year="2007",
author="Toren, Paz and Ratner, Sharon and Weizman, Abraham and Lask, Michal and Ben-Amitay, Galit and Laor, Nathaniel",
volume="17",
number="6",
pages="803-812",
abstract="OBJECTIVE: This open-label study assessed the long-term effectiveness and tolerability of reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: Six children aged 9-13 (mean +/- standard deviation, SD, 10.7 +/- 1.6) years, diagnosed with ADHD and successfully treated with reboxetine for 6 weeks were enrolled in a long-term (18-36 months) follow-up study. Assessments included rater-administered scales (ADHD Rating Scale; Clinical Global Impressions Scale) and a parent-administered scale (the Abbreviated Conners' Rating Scale). The safety and tolerability were evaluated by documenting spontaneous self-reported adverse effects as well as by vital signs, electrocardiogram, body weight, and routine blood screen. Reboxetine was maintained at a dose of 4 mg/day. RESULTS: The children were followed up to 36 months (mean +/- SD, 24 +/- 6.6; range, 18-36). The significant decrease in ADHD symptoms achieved in the short-term phase (first 6 weeks) was maintained throughout the study. No new onset adverse effects was detected during this follow-up period. No suicidal attempt or ideation was noted. CONCLUSIONS: The results suggest the long-term effectiveness and safety of reboxetine maintenance treatment in children with ADHD. Future large-scale, long-term, placebo/comparator-controlled studies should assess the benefit/risk ratio of reboxetine in ADHD children.<p /><p>Language: en</p>",
language="en",
issn="1044-5463",
doi="10.1089/cap.2006.0145",
url="http://dx.doi.org/10.1089/cap.2006.0145"
}